Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,090
  • Shares Outstanding, K 31,503
  • Annual Sales, $ 25,180 K
  • Annual Income, $ -22,290 K
  • 60-Month Beta 3.99
  • Price/Sales 6.94
  • Price/Cash Flow N/A
  • Price/Book 8.08
Trade CAPR with:

Options Overview Details

View History
  • Implied Volatility 125.21% ( -15.74%)
  • Historical Volatility 76.13%
  • IV Percentile 80%
  • IV Rank 24.71%
  • IV High 366.57% on 10/18/23
  • IV Low 46.01% on 05/10/23
  • Put/Call Vol Ratio 0.20
  • Today's Volume 214
  • Volume Avg (30-Day) 159
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 6,219
  • Open Int (30-Day) 5,868

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.11
  • Number of Estimates 1
  • High Estimate -0.11
  • Low Estimate -0.11
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +64.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.68 +6.94%
on 04/18/24
7.28 -31.18%
on 04/01/24
-1.78 (-26.22%)
since 03/19/24
3-Month
3.56 +40.73%
on 02/16/24
7.28 -31.18%
on 04/01/24
+0.98 (+24.32%)
since 01/19/24
52-Week
2.68 +86.94%
on 11/10/23
8.22 -39.06%
on 08/28/23
+0.78 (+18.44%)
since 04/19/23

Most Recent Stories

More News
Capricor: Q4 Earnings Snapshot

Capricor: Q4 Earnings Snapshot

CAPR : 5.01 (-0.79%)
Capricor: Q3 Earnings Snapshot

Capricor: Q3 Earnings Snapshot

CAPR : 5.01 (-0.79%)
24 Cent Micro Cap May Hold The Key To Potential Breakthrough In Acute Spinal Cord Injury

An estimated 250,000-500,000 people experience a %SpinalCordInjury (SCI) annually, with roughly 17,000 new cases in the US and 27,000 in Europe each year, leaving many of those people permanently confined...

TECH : 62.12 (-0.14%)
LLY : 726.31 (-2.63%)
CAPR : 5.01 (-0.79%)
NRX.VN : 0.580 (-3.33%)
NRX : 0.14 (+7.69%)
PARS : 0.0200 (-48.72%)
Capricor: Q2 Earnings Snapshot

Capricor: Q2 Earnings Snapshot

CAPR : 5.01 (-0.79%)
Capricor: Q1 Earnings Snapshot

Capricor: Q1 Earnings Snapshot

CAPR : 5.01 (-0.79%)
Capricor: Q4 Earnings Snapshot

Capricor: Q4 Earnings Snapshot

CAPR : 5.01 (-0.79%)
Capricor (CAPR) Upgraded to Buy: What Does It Mean for the Stock?

Capricor (CAPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CAPR : 5.01 (-0.79%)
Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

CAPR : 5.01 (-0.79%)
RMTI : 1.4500 (-2.03%)
Capricor: Q3 Earnings Snapshot

Capricor: Q3 Earnings Snapshot

CAPR : 5.01 (-0.79%)
Capricor Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

-First Patient Treated in HOPE-3, the Pivotal Phase 3 Clinical Trial of CAP-1002 in Duchenne Muscular Dystrophy- -Positive One-Year...

CAPR : 5.01 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 5.65
2nd Resistance Point 5.46
1st Resistance Point 5.24
Last Price 5.01
1st Support Level 4.83
2nd Support Level 4.64
3rd Support Level 4.42

See More

52-Week High 8.22
Fibonacci 61.8% 6.10
Fibonacci 50% 5.45
Last Price 5.01
Fibonacci 38.2% 4.80
52-Week Low 2.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar